Trial
NCT01369888
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Metastatic Melanoma
Intervention
Cyclophosphamide
Why stopped
Closed this protocol due to autoimmune toxicity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-27